SCYNEXIS, Inc. (SCYX)
SCYX Stock Price Chart
Explore SCYNEXIS, Inc. interactive price chart. Choose custom timeframes to analyze SCYX price movements and trends.
SCYX Company Profile
Discover essential business fundamentals and corporate details for SCYNEXIS, Inc. (SCYX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
2 May 2014
Employees
18.00
Website
https://www.scynexis.comCEO
David Angulo
Description
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
SCYX Financial Timeline
Browse a chronological timeline of SCYNEXIS, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.51, while revenue estimate is $80.33k.
Stock split effective on 1 Jun 2026
Shares were split 1 : 8 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 May 2026
EPS came in at -$3.36 falling short of the estimated -$0.80 by -320.00%.
Earnings released on 4 Mar 2026
EPS came in at $0.25 falling short of the estimated $0.29 by -13.79%, while revenue for the quarter reached $18.65m , beating expectations by +130.20%.
Earnings released on 5 Nov 2025
EPS came in at -$0.17 surpassing the estimated -$0.21 by +19.05%, while revenue for the quarter reached $334.00k , beating expectations by +150.50%.
Earnings released on 14 Aug 2025
EPS came in at -$0.14 surpassing the estimated -$0.23 by +39.13%, while revenue for the quarter reached $1.36m , beating expectations by +785.71%.
Earnings released on 16 May 2025
EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%, while revenue for the quarter reached $257.00k , beating expectations by +87.59%.
Earnings released on 12 Mar 2025
EPS came in at -$0.09 falling short of the estimated -$0.02 by -350.00%, while revenue for the quarter reached $977.00k , missing expectations by -90.41%.
Earnings released on 6 Nov 2024
EPS came in at -$0.06 surpassing the estimated -$0.20 by +70.00%, while revenue for the quarter reached $660.00k , missing expectations by -89.32%.
Earnings released on 8 Aug 2024
EPS came in at -$0.30 falling short of the estimated -$0.19 by -57.89%, while revenue for the quarter reached $736.00k , beating expectations by +162.86%.
Earnings released on 8 May 2024
EPS came in at -$0.15 surpassing the estimated -$0.18 by +16.67%, while revenue for the quarter reached $1.37m , beating expectations by +472.08%.
Earnings released on 29 Mar 2024
EPS came in at -$0.39 falling short of the estimated -$0.06 by -578.26%, while revenue for the quarter reached $5.80m , missing expectations by -24.19%.
Earnings released on 13 Nov 2023
EPS came in at -$0.04 surpassing the estimated -$0.13 by +70.15%, while revenue for the quarter reached $1.76m , missing expectations by -70.12%.
Earnings released on 14 Aug 2023
EPS came in at $2.46 surpassing the estimated $1.03 by +138.83%, while revenue for the quarter reached $131.45m , beating expectations by +37.79%.
Earnings released on 11 May 2023
EPS came in at -$0.25 surpassing the estimated -$0.28 by +10.71%, while revenue for the quarter reached $1.13m , beating expectations by +32.13%.
Earnings released on 31 Mar 2023
EPS came in at -$0.29 surpassing the estimated -$0.50 by +42.00%, while revenue for the quarter reached $1.40m , beating expectations by +22.14%.
Earnings released on 9 Nov 2022
EPS came in at -$0.62 falling short of the estimated -$0.51 by -21.57%, while revenue for the quarter reached $1.56m , missing expectations by -26.19%.
Earnings released on 15 Aug 2022
EPS came in at -$0.53 surpassing the estimated -$0.57 by +7.02%, while revenue for the quarter reached $1.32m , missing expectations by -21.17%.
Earnings released on 12 May 2022
EPS came in at -$0.18 surpassing the estimated -$0.74 by +75.68%, while revenue for the quarter reached $687.00k , missing expectations by -36.97%.
Earnings released on 29 Mar 2022
EPS came in at -$1.05 falling short of the estimated -$0.71 by -47.89%, while revenue for the quarter reached $597.00k , missing expectations by -52.59%.
Earnings released on 10 Nov 2021
EPS came in at -$0.06 surpassing the estimated -$0.79 by +92.41%, while revenue for the quarter reached $516.00k , missing expectations by -42.25%.
Earnings released on 16 Aug 2021
EPS came in at -$0.22 surpassing the estimated -$0.58 by +62.07%.
SCYX Stock Performance
Access detailed SCYX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
